mifepristone has been researched along with B16 Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, H; Gao, Y; Jia, L; Li, T; Lu, Y; Ma, J; Shao, J; Tu, X; Wan, L; Wang, J; Xie, F; Xie, J; Xu, B; Xu, H; Zhang, T; Zhu, Y | 1 |
| Chen, J; Dong, H; Jia, L; Liu, J; Lu, Y; Shao, J; Wang, J; Xiao, Y; Xie, J; Yu, S; Zheng, N; Zhu, Y | 1 |
| Lindemeyer, RG; Litwack, G; Robertson, NM | 1 |
3 other study(ies) available for mifepristone and B16 Melanoma
| Article | Year |
|---|---|
Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Doxycycline; Drug Interactions; Female; Human Umbilical Vein Endothelial Cells; Humans; Lysine; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mifepristone; Neoplasm Metastasis; Random Allocation; Rats; Rats, Sprague-Dawley | 2015 |
In vitro and in vivo efficacy and safety evaluation of metapristone and mifepristone as cancer metastatic chemopreventive agents.
Topics: Animals; Anticarcinogenic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoprevention; Disease Models, Animal; Female; Integrin alpha4; Liver; Lung Neoplasms; Melanoma, Experimental; Mice, Inbred C57BL; Mifepristone; Treatment Outcome | 2016 |
Glucocorticoid receptor monoclonal antibodies define the biological action of RU 38486 in intact B16 melanoma cells.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Cell Nucleus; Cortodoxone; Fluorescent Antibody Technique; Immunoglobulin M; Melanoma, Experimental; Mice; Mifepristone; Receptors, Glucocorticoid; Triamcinolone Acetonide | 1990 |